Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMINI-PeriOp GC perioperative novel agents in resectable gastroesophageal adenocarcinoma
jRCT2031250230Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2 trial of sonesitatug vedotin, trastuzumab deruxtecan and rilvegostomig in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma and esophageal adenocarcinoma (EAC) (3 arms), sponsored by AstraZeneca. Primary endpoints: Number of participants with adverse events (AEs) and serious adverse events (SAEs) and Percentage of participants with pathological complete response (pCR). Started Jul 2025; status: recruiting.
02
Drugs
sonesitatug vedotintrastuzumab deruxtecanrilvegostomig
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on jRCT2031250230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250230.